NUCALA PROVIDED EARLY AND SUSTAINED IMPROVEMENTS IN NASAL OBSTRUCTION/CONGESTION

Reduction in nasal polyp obstruction and size1,2

Co-primary endpoint: significant improvement in nasal obstruction score.* Weeks 49-52; P<0.001.

Reduced nasal obstruction graph Reduced nasal obstruction graph

Results prior to Weeks 49-52 are descriptive.

Placebo + SOC (n=201; baseline score, 9.0)

NUCALA + SOC (n=206; baseline score, 8.9)

Co-primary endpoint: significant improvement in nasal polyp size.

LS mean† change from baseline in total endoscopic nasal polyp score‡ at Week 52: NUCALA, –0.87 (baseline: 5.4) vs placebo, 0.06 (baseline: 5.6), P<0.001.

*Symptom severity measured on patient-reported VAS from 0 (none) to 10 (as bad as you can imagine).

†LS means from an analysis using mixed–model repeated measures.

‡Total score (sum of scores for both nostrils) ranged from 0 to 8.

Results are descriptive from co-primary endpoint.

Co-primary endpoint: significant improvement in nasal polyp size.

LS mean† change from baseline in total endoscopic nasal polyp score‡ at Week 52: NUCALA, –0.87 (baseline: 5.4) vs placebo, 0.06 (baseline: 5.6), P<0.001.

*Symptom severity measured on patient-reported VAS from 0 (none) to 10 (as bad as you can imagine).

†LS means from an analysis using mixed–model repeated measures.

‡Total score (sum of scores for both nostrils) ranged from 0 to 8.

SYNAPSE study design

LS=least squares; SOC=standard of care; VAS=visual analog scale.

Request a rep

Want to know more?

Request a rep
 
Nasal symptom improvement

Learn how NUCALA significantly improved loss of smell

SEE SYMPTOM DATA

NUCALA Prescription

Navigate a NUCALA prescription

Get patients started